The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
To assess whether treatment with one of three novel biological DMARDs; rituximab, abatacept or tocilizumab reduce cardiovascular disease (CVD) risk factors in patients with rheumatoid arthritis (RA).This is an open, observational and prospective study with visits at baseline, 3, 6, and 12 months. Pa...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Public Library of Science (PLoS)
2015-01-01
|
| Серія: | PLoS ONE |
| Онлайн доступ: | http://europepmc.org/articles/PMC4482693?pdf=render |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|